515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
| Autor: | Lim, J.S., Sundar, R., Wong, A., Yong, W-P., Soo, R., Chee, C.E., Lee, S.C., Goh, B.C., Dent, R., Jeraj, S. d/o Nathan, Kwok, L., Schiavon, G., Kaliaperumal, N., Foxley, A., Connolly, J.E., Tan, D.S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S585-S586 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|